{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:47:19Z","timestamp":1791946039744,"version":"4.3.4"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.autrev.2016.01.004","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T12:00:32Z","timestamp":1453377632000},"page":"397-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["The role of IL-17 in vitiligo: A review"],"prefix":"10.1016","volume":"15","author":[{"given":"Rasnik K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Vujkovic-Cvijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Ucmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Farahnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.01.004_bb0005","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.01.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2013.58","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.autrev.2016.01.004_bb0015","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: an effector CD4 T cell lineage with regulatory T cell ties","volume":"24","author":"Weaver","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2016.01.004_bb0020","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F","volume":"205","author":"Yang","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2016.01.004_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.01.004_bb0040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0045","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0050","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0060","doi-asserted-by":"crossref","unstructured":"Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg n.d.;19:109\u201314. doi:10.2310\/7750.2014.14038.","DOI":"10.2310\/7750.2014.14038"},{"key":"10.1016\/j.autrev.2016.01.004_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CCID.S67534","article-title":"Targeting of interleukin-17 in the treatment of psoriasis","volume":"7","author":"L\u00f8nnberg","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/09546634.2013.878448","article-title":"Anti-IL-17 phase II data for psoriasis: a review","volume":"26","author":"Brown","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2016.01.004_bb0075","series-title":"Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 March 20","article-title":"Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1)","author":"Gordon","year":"2015"},{"key":"10.1016\/j.autrev.2016.01.004_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2016.01.004_bb0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.01.004_bb0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1016-8478(23)13153-0","article-title":"Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients","volume":"19","author":"Hwang","year":"2005","journal-title":"Mol Cells"},{"key":"10.1016\/j.autrev.2016.01.004_bb0095","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10067-011-1737-y","article-title":"Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA","volume":"30","author":"Metawi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1759720X13485328","article-title":"Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential","volume":"5","author":"Kellner","year":"2013","journal-title":"Ther Adv Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2016.01.004_bb0105","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2013.08.006","article-title":"The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies","volume":"13","author":"Novelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.01.004_bb0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.01.004_bb0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/art.10173","article-title":"Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein","volume":"46","author":"Bush","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.01.004_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2016.01.004_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","article-title":"Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination","volume":"333","author":"Rostami","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2016.01.004_bb0135","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1096\/fj.09-141978","article-title":"Cellular mechanisms of IL-17-induced blood\u2013brain barrier disruption","volume":"24","author":"Huppert","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2016.01.004_bb0140","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.autrev.2014.08.022","article-title":"Unmasking the pathogenic role of IL-17 axis in primary Sj\u00f6gren's syndrome: a new era for therapeutic targeting?","volume":"13","author":"Alunno","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.01.004_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0150","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.4049\/jimmunol.1200955","article-title":"Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis","volume":"189","author":"Cao","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0155","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2016.01.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.07.084","article-title":"Mo2083 A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease","volume":"143","author":"Targan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2016.01.004_bb0165","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/mi.2011.24","article-title":"IL-17: intestinal effector or protector?","volume":"4","author":"Fuss","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0170","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3109\/08830185.2013.821118","article-title":"Inhibition of IL-17 as a pharmacological approach for IBD","volume":"32","author":"Fitzpatrick","year":"2013","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0175","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.01.004_bb0180","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/jid.2011.12","article-title":"Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset","volume":"131","author":"Jin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng.603","article-title":"Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC","volume":"42","author":"Quan","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2016.01.004_bb0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3346\/jkms.2013.28.5.775","article-title":"Three new single nucleotide polymorphisms identified by a genome-wide association study in Korean patients with vitiligo","volume":"28","author":"Cheong","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2016.01.004_bb0195","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0200","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1523-1747.2001.00000.x","article-title":"The neurosensory system controls keratinocyte release of growth and survival factor nerve growth factor","volume":"117","author":"Norris","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0002-9440(10)63294-4","article-title":"Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor","volume":"165","author":"Peters","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1523-1747.ep12492607","article-title":"Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo","volume":"97","author":"Harning","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0625.2010.01181.x","article-title":"Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo","volume":"20","author":"Kemp","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cei.12146","article-title":"Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo","volume":"174","author":"You","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0225","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T Lymphocytes in Vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0230","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2016.01.004_bb0235","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2133.2009.09217.x","article-title":"Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus","volume":"161","author":"Taher","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0240","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00403-009-0964-4","article-title":"Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo","volume":"301","author":"Khan","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","article-title":"Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies","volume":"181","author":"Maddur","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0250","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0255","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.01.004_bb0260","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0265","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-\u03b2) in patients with vitiligo","volume":"66","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0270","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","article-title":"The role of helper and regulatory T cells in the pathogenesis of vitiligo","volume":"60","author":"Basak","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0275","doi-asserted-by":"crossref","unstructured":"Elela MA, Hegazy RA, Fawzy MM, Rashed LA, Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients. Eur J Dermatol n.d.;23:350\u20135. doi:10.1684\/ejd.2013.2023.","DOI":"10.1684\/ejd.2013.2023"},{"key":"10.1016\/j.autrev.2016.01.004_bb0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2016.01.004_bb0285","first-page":"81","article-title":"Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients","volume":"10","author":"Esmaeili","year":"2011","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0290","article-title":"Expression of interleukin-17 mRNA in vitiligo patients","volume":"33","author":"Habeb","year":"2013","journal-title":"Egypt J Dermatol Venerol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0295","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1711700209","article-title":"An immunohistological study of cutaneous lymphocytes in vitiligo","volume":"170","author":"Badri","year":"1993","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0300","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0305","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2016.01.004_bb0310","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1755-148X.2011.00945.x","article-title":"Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris","volume":"25","author":"Kotobuki","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/exd.12369","article-title":"T helper 17 and tregs: a novel proposed mechanism for NB-UVB in vitiligo","volume":"23","author":"Hegazy","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0320","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2008.07.053","article-title":"Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review","volume":"60","author":"Nicolaidou","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0325","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13988","article-title":"Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma","author":"Malerba","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0330","first-page":"1300","article-title":"Treatment of BCG polysaccharide nucleic acid combined with CO2 laser reduces Th17 cells and their related cytokines in cutaneous lesion of vitiligo patients","volume":"30","author":"Zhan","year":"2014","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.autrev.2016.01.004_bb0335","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/pcmr.12284","article-title":"Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation","volume":"27","author":"Eby","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0340","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0345","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.1401082","article-title":"The inducible costimulator augments Tc17 cell responses to self and tumor tissue","volume":"194","author":"Nelson","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0350","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2016.01.004_bb0355","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4049\/jimmunol.180.1.214","article-title":"Human T cells that are able to produce IL-17 express the chemokine receptor CCR6","volume":"180","author":"Singh","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0360","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2016.01.004_bb0365","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","article-title":"Tumor-specific Th17-polarized cells eradicate large established melanoma","volume":"112","author":"Muranski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2016.01.004_bb0370","doi-asserted-by":"crossref","unstructured":"Zhang B-X, Lin M, Qi X-Y, Zhang R-X, Wei Z-D, Zhu J, et al. Characterization of circulating CD8+T cells expressing skin homing and cytotoxic molecules in active non-segmental vitiligo. Eur J Dermatol n.d.;23:331\u20138. doi:10.1684\/ejd.2013.2011.","DOI":"10.1684\/ejd.2013.2011"},{"key":"10.1016\/j.autrev.2016.01.004_bb0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/mmr.2012.1117","article-title":"CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis","volume":"7","author":"Wu","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2016.01.004_bb0380","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/ijd.12160","article-title":"Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo","volume":"53","author":"Abdallah","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0385","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.01.004_bb0390","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/1523-1747.ep12556058","article-title":"Neutrophil-activating proteins in psoriasis","volume":"98","author":"Schr\u00f6der","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0395","first-page":"1219","article-title":"Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance","volume":"148","author":"Le Poole","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0400","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2133.1984.tb04037.x","article-title":"Neutral proteinases and other neutrophil enzymes in psoriasis, and their relation to disease activity","volume":"111","author":"Gli\u0144ski","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0405","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0300060513516294","article-title":"Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy","volume":"42","author":"Karsli","year":"2014","journal-title":"J Int Med Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0410","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00403-005-0565-9","article-title":"Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells","volume":"297","author":"Sigmundsdottir","year":"2005","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0415","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2133.2010.09992.x","article-title":"Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-\u03b1 levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy","volume":"163","author":"Coimbra","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0420","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0749.1994.tb00049.x","article-title":"Melanocyte destruction and repopulation in vitiligo","volume":"7","author":"Norris","year":"1994","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0425","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.4049\/jimmunol.0903271","article-title":"IL-17 contributes to angiogenesis in rheumatoid arthritis","volume":"184","author":"Pickens","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0430","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/eji.201040707","article-title":"Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells","volume":"40","author":"Silva-Santos","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2016.01.004_bb0435","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2011.03.021","article-title":"IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma","volume":"407","author":"Liu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2016.01.004_bb0440","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00403-010-1040-9","article-title":"Increased angiogenesis and mast cells in the centre compared to the periphery of vitiligo lesions","volume":"302","author":"Aroni","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2016.01.004_bb0445","doi-asserted-by":"crossref","unstructured":"Stylianos V, Eleftherios I, Nikolaos K, Kyriaki A. Correlating epidermal thickness and basement membrane length to angiogenesis in the centre and the periphery of vitiligo lesion. Indian J Dermatol Venereol Leprol n.d.;78:368\u201371. doi:10.4103\/0378-6323.95462.","DOI":"10.4103\/0378-6323.95462"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721600015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721600015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T18:28:23Z","timestamp":1718303303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721600015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S156899721600015X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.01.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726695901.793522581","asserted-by":"object"}]},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of IL-17 in vitiligo: A review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}